Table of Contents
<< Previous Issue | Nov 2020 (Vol: 2020, Issue: 11) | Next Issue >> |
- Section: Licensing
-
Novartis Licenses Mesoblast’s Stem Cell Therapy Remestemcel-L
- Section: Mergers & Acquisitions
-
Merck & Co. Continues Oncology Expansion with US$2.75 B VelosBio Buy
-
Novo Nordisk Acquires Emisphere’s Eligen® Technology for US$1.8 B